Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.50 |
| ▸ | IDO1 | P14902 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | AGXT | P21549 | 2/20 | 0.48 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.46 |
| ▸ | HTR3B | O95264 | 3/20 | 0.46 |
| ▸ | HTR3A | P46098 | 3/20 | 0.46 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.46 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1004527 | 0.80 | TAAR1 (0.57) | PNMTTAAR1IDO1CYP3A4AGXT | |
| SCHEMBL11152109 | 0.79 | TAAR1 (0.57) | PNMTTAAR1IDO1CYP3A4AGXT | |
| SCHEMBL6291666 | 0.77 | TSHR (0.42) | PNMTIDO1CYP3A4HTR3EHTR3B | |
| SCHEMBL11154355 | 0.76 | TAAR1 (0.53) | PNMTTAAR1IDO1CYP3A4AGXT | |
| SCHEMBL613603 | 0.76 | TAAR1 (0.52) | TAAR1IDO1AGXTMAOB | |
| SCHEMBL5733314 | 0.75 | PNMT (0.60) | PNMTTAAR1IDO1CYP3A4AGXT | |
| SCHEMBL2436 | 0.75 | — | — | |
| SCHEMBL29353832 | 0.75 | — | — | |
| SCHEMBL933385 | 0.74 | TAAR1 (0.50) | TAAR1IDO1MAOB | |
| SCHEMBL1538033 | 0.74 | TAAR1 (0.50) | TAAR1IDO1AGXTMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713318-A2 | SMALL MOLECULE MODULATORS OF IL-17A, METHODS OF MAKING AND METHODS OF USING THEREOF | ASCLETIS PHARMA (CHINA) CO., LIMITED (HK) | 2026-03-25 | — | — | EP | disclosed |
| EP-3719018-B1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2025-08-27 | — | — | EP | disclosed |
| US-20250011303-A1 | SMALL MOLECULE MODULATORS OF IL-17A, METHODS OF MAKING AND METHODS OF USING THEREOF | ASCLETIS PHARMA (CHINA) CO., LIMITED (CN) | 2025-01-09 | — | — | US | disclosed |
| WO-2024235303-A2 | SMALL MOLECULE MODULATORS OF IL-17A, METHODS OF MAKING AND METHODS OF USING THEREOF | ASCLETIS BIOSCIENCE CO., LTD. (CN) | 2024-11-21 | — | — | WO | disclosed |
| EP-3421471-B1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2021-05-26 | — | — | EP | disclosed |
| EP-3719018-A1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Ltd (GB) | 2020-10-07 | — | — | EP | disclosed |
| EP-3421471-A1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2019-01-02 | — | — | EP | disclosed |
| EP-2272517-B2 | ORTHO -CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E.G. PURINES) AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2017-09-20 | — | — | EP | disclosed |
| US-9006430-B2 | Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein | ASTEX THERAPEUTICS LIMITED (GB) | 2015-04-14 | — | — | US | disclosed |
| US-20140303177-A1 | ORTHO-CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E.G., PURINES) AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2014-10-09 | — | — | US | disclosed |
| EP-1812004-B1 | ORTHO- CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E. G. PURINES) AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2011-06-22 | — | — | EP | disclosed |
| US-7902252-B2 | Inhibitors of D-amino acid oxidase | SEPRACOR, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| WO-2011011330-A2 | INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2011-01-27 | — | — | WO | disclosed |
| EP-2272517-A1 | Ortho-condensed pyridine and pyrimidine derivatives ( e.g. purines ) as protein kinases inhibitors | Astex Therapeutics Limited (GB) | 2011-01-12 | — | — | EP | disclosed |
| US-20100029737-A1 | INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100022564-A1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
| US-20090247538-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | ASTEX THERAPEUTICS LIMITED (UK) | 2009-10-01 | — | — | US | disclosed |
| EP-2043655-A2 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2009-04-08 | — | — | EP | disclosed |
| WO-2007125321-A2 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
| WO-2006046024-A1 | ORTHO- CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E. G. PURINES) AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247538-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | CDK2, CDK1, OXSR1 | PNMT 2033/4885TAAR1 1131/4885IDO1 3724/4885 |
| US-20140303177-A1 | ORTHO-CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E.G., PURINES) AS PROTEIN KINASES INHIBITORS | CDK2, CDK1, CDK3 | PNMT 1966/4885TAAR1 1192/4885IDO1 3734/4885 |
| US-20100029737-A1 | INHIBITORS OF D-AMINO ACID OXIDASE | DDO, DAO, ACHE | PNMT 81/4885TAAR1 1412/4885IDO1 694/4885 |
| US-20250011303-A1 | SMALL MOLECULE MODULATORS OF IL-17A, METHODS OF MAKING AND METHODS OF USING THEREOF | IL17A, IL15, IL23R | PNMT 2835/4885TAAR1 4169/4885IDO1 1166/4885 |
| US-20100022564-A1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | TPMT, CNKSR1, PRKD3 | PNMT 2276/4885TAAR1 2190/4885IDO1 2774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.